In Vitro activity of the novel antimicrobial peptide dendrimer G3KL against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7915-7918

  Pires, João ^a   Siriwardena, Thissa N ^a   Stach, Michaela ^a   Tinguely, Regula ^a   Kasraian, Sara ^a   Luzzaro, Francesco ^b   Leib, Stephen L ^a,c   Darbre, Tamis ^a   Reymond, Jean Louis ^a   Endimiani, Andrea ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b A MANZONI HOSPITAL   (Italy)

^c SPIEZ LABORATORY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

G 3KL; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BACTERIAL PROTEIN; BETA LACTAM; BETA LACTAMASE; CARBAPENEMASE; DENDRIMER; ISOENZYME;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; MIC50; MIC90; MINIMUM BACTERICIDAL CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; CHEMICAL STRUCTURE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; SYNTHESIS;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; DENDRIMERS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION; ISOENZYMES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PSEUDOMONAS AERUGINOSA;

EID: 84954522031     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01853-15     Document Type: Article

References (33)

1. Diene SM, Rolain JM. 2014. Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species. Clin Microbiol Infect 20:831-838. http://dx.doi.org/10.1111/1469-0691.12655.
2. Spellberg B, Bonomo RA. 2015. Combination therapy for extreme drugresistant Acinetobacter baumannii: ready for prime time? Crit Care Med 43:1332-1334. http://dx.doi.org/10.1097/CCM.0000000000001029.
3. Doi Y, Murray GL, Peleg AY. 2015. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 36:85-98. http://dx.doi.org/10.1055/s-0034-1398388.
4. Viale P, Giannella M, Tedeschi S, Lewis R. 2015. Treatment of MDRGram negative infections in the 21st century: a never ending threat for clinicians. Curr Opin Pharmacol 24:30-37. http://dx.doi.org/10.1016/j.coph.2015.07.001.
5. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268-281. http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x.
6. Agodi A, Voulgari E, Barchitta M, Quattrocchi A, Bellocchi P, Poulou A, Santangelo C, Castiglione G, Giaquinta L, Romeo MA, Vrioni G, Tsakris A. 2014. Spread of a carbapenem-and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals. J Hosp Infect 86:260-266. http://dx.doi.org/10.1016/j.jhin.2014.02.001.
7. Durante-Mangoni E, Del Franco M, Andini R, Bernardo M, Giannouli M, Zarrilli R. 2015. Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 82: 222-226. http://dx.doi.org/10.1016/j.diagmicrobio.2015.03.013.
8. Lopez-Rojas R, McConnell MJ, Jimenez-Mejias ME, Dominguez-Herrera J, Fernandez-Cuenca F, Pachon J. 2013. Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. Antimicrob Agents Chemother 57:4587-4589. http://dx.doi.org/10.1128/AAC.00543-13.
9. Cheung RC, Ng TB, Wong JH. 2015. Marine peptides: bioactivities and applications. Mar Drugs 13:4006-4043. http://dx.doi.org/10.3390/md13074006.
10. Mojsoska B, Jenssen H. 2015. Peptides and peptidomimetics for antimicrobial drug design. Pharmaceuticals 8:366-415. http://dx.doi.org/10.3390/ph8030366.
11. Peters BM, Shirtliff ME, Jabra-Rizk MA. 2010. Antimicrobial peptides: primeval molecules or future drugs? PLoS Pathog 6:e1001067. http://dx.doi.org/10.1371/journal.ppat.1001067.
12. McGrath DM, Barbu EM, Driessen WHP, Lasco TM, Tarrand JJ, Okhuysen PC, Kontoyiannis DP, Sidman RL, Pasqualini R, Arap W. 2013. Mechanism of action and initial evaluation of a membrane active all-D-enantiomer antimicrobial peptidomimetic. Proc Natl Acad Sci U S A 110:3477-3482. http://dx.doi.org/10.1073/pnas.1221924110.
13. Ueno S, Minaba M, Nishiuchi Y, Taichi M, Tamada Y, Yamazaki T, Kato Y. 2011. Generation of novel cationic antimicrobial peptides from natural non-antimicrobial sequences by acid-amide substitution. Ann Clin Microbiol Antimicrob 10:11. http://dx.doi.org/10.1186/1476-0711-10-11.
14. Vila-Farres X, Garcia de la Maria C, López-Rojas R, Pachón J, Giralt E, Vila J. 2012. In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin Microbiol Infect 18:383-387. http://dx.doi.org/10.1111/j.1469-0691.2011.03581.x.
15. Sanchez-Gomez S, Ferrer-Espada R, Stewart PS, Pitts B, Lohner K, Martinez de Tejada G. 2015. Antimicrobial activity of synthetic cationic peptides and lipopeptides derived from human lactoferricin against Pseudomonas aeruginosa planktonic cultures and biofilms. BMC Microbiol 15:137. http://dx.doi.org/10.1186/s12866-015-0473-x.
16. Mintzer MA, Dane EL, O'Toole GA, Grinstaff MW. 2012. Exploiting dendrimer multivalency to combat emerging and re-emerging infectious diseases. Mol Pharm 9:342-354. http://dx.doi.org/10.1021/mp2005033.
17. Reymond JL, Darbre T. 2012. Peptide and glycopeptide dendrimer apple trees as enzyme models and for biomedical applications. Org Biomol Chem 10:1483-1492. http://dx.doi.org/10.1039/c2ob06938e.
18. Reymond JL, Bergmann M, Darbre T. 2013. Glycopeptide dendrimers as Pseudomonas aeruginosa biofilm inhibitors. Chem Soc Rev 42:4814-4822. http://dx.doi.org/10.1039/c3cs35504g.
19. Fluxa VS, Maillard N, Page MG, Reymond JL. 2011. Bead diffusion assay for discovering antimicrobial cyclic peptides. Chem Commun (Camb) 47:1434-1436. http://dx.doi.org/10.1039/C0CC04670A.
20. Stach M, Maillard N, Kadam RU, Kalbermatter D, Meury M, Page MGP, Fotiadis D, Darbre T, Reymond J-L. 2012. Membrane disrupting antimicrobial peptide dendrimers with multiple amino termini. Medchemcomm 3:86-89. http://dx.doi.org/10.1039/C1MD00272D.
21. Stach M, Siriwardena TN, Kohler T, van Delden C, Darbre T, Reymond JL. 2014. Combining topology and sequence design for the discovery of potent antimicrobial peptide dendrimers against multidrug-resistant Pseudomonas aeruginosa. Angew Chem Int Ed Engl 53:12827-12831. http: //dx.doi.org/10.1002/anie.201409270.
22. Ravi HK, Stach M, Soares TA, Darbre T, Reymond JL, Cascella M. 2013. Electrostatics and flexibility drive membrane recognition and early penetration by the antimicrobial peptide dendrimer bH1. Chem Commun (Camb) 49:8821-8823. http://dx.doi.org/10.1039/c3cc44912b.
23. CLSI. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. M100-S24. CLSI, Wayne, PA.
24. CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. Document M7-A9. CLSI, Wayne, PA.
25. Mahon CR, Manuselis G. 2000. Textbook of diagnostic microbiology, 2nd ed. W.B. Saunders Company, St. Louis, MO.
26. Principe L, Piazza A, Giani T, Bracco S, Caltagirone MS, Arena F, Nucleo E, Tammaro F, Rossolini GM, Pagani L, Luzzaro F. 2014. Epidemic diffusion of OXA-23-producing Acinetobacter baumannii isolates in Italy: results of the first cross-sectional countrywide survey. J Clin Microbiol 52:3004-3010. http://dx.doi.org/10.1128/JCM.00291-14.
27. Docquier JD, Luzzaro F, Amicosante G, Toniolo A, Rossolini GM. 2001. Multidrug-resistant Pseudomonas aeruginosa producing PER-1 extended-spectrum serine-β-lactamase and VIM-2 metallo-β-lactamase. Emerg Infect Dis 7:910-911. http://dx.doi.org/10.3201/eid0705.010528.
28. D'Andrea MM, Giani T, D'Arezzo S, Capone A, Petrosillo N, Visca P, Luzzaro F, Rossolini GM. 2009. Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 53:3528-3533. http://dx.doi.org/10.1128/AAC.00178-09.
29. Luzzaro F, Ortisi G, Larosa M, Drago M, Brigante G, Gesu G. 2011. Prevalence and epidemiology of microbial pathogens causing bloodstream infections: results of the OASIS multicenter study. Diagn Microbiol Infect Dis 69:363-369. http://dx.doi.org/10.1016/j.diagmicrobio.2010.10.016.
30. French GL. 2006. Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin. J Antimicrob Chemother 58: 1107-1117. http://dx.doi.org/10.1093/jac/dkl393.
31. Giacometti A, Cirioni O, Del Prete MS, Barchiesi F, Paggi AM, Petrelli E, Scalise G. 2000. Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother 46: 807-810. http://dx.doi.org/10.1093/jac/46.5.807.
32. Lind TK, Polcyn P, Zielinska P, Cardenas M, Urbanczyk-Lipkowska Z. 2015. On the antimicrobial activity of various peptide-based dendrimers of similar architecture. Molecules 20:738-753. http://dx.doi.org/10.3390 /molecules20010738.
33. Bahar AA, Liu Z, Totsingan F, Buitrago C, Kallenbach N, Ren D. 2015. Synthetic dendrimeric peptide active against biofilm and persister cells of Pseudomonas aeruginosa. Appl Microbiol Biotechnol 99:8125-8135. http: //dx.doi.org/10.1007/s00253-015-6645-7.